Navigation Links
Global Cystic Fibrosis Heat Map and Analysis 2016-2022 - Research and Markets
Date:1/13/2017

DUBLIN, Jan 13, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Cystic Fibrosis - Heat Map and Analysis" report to their offering.

Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body's epithelial cells, and result in the buildup of a thick and sticky mucus in the lungs and pancreas.

Historically therapeutic options have focused heavily on treating the symptoms, but despite being clinically and commercially successful have failed to address the faulty CFTR proteins that cause the disease. This unmet need has led to the development of CFTR modulators.

The treatment algorithm patients receive is likely to consist of an antimicrobial, a mucolytic agent, pancreatic enzymes and possibly a CFTR modulator. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CF market and Phase III or Preregistration stages of the pipeline. These are split along drug class lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

- To what extent is the CF market landscape expected to change with the introduction of new CFTR modulators?
- What are the clinical characteristics of currently approved therapies for CF, in terms of specific safety and efficacy parameters?
- What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
- How will current late-stage CFTR modulators affect the market for symptomatic therapies, and are they able to yield comparable clinical efficacy results to Kalydeco?
- How will the influx of tobramycin generics affect the competitive landscape?

Key Topics Covered:

1. Table of Contents

2. Introduction
2.1 Report Guidance

3. Marketed Products
3.1 Antimicrobeals
3.2 Mucolytic Agents
3.3 Pancreatic Enzymes
3.4 CFTR modulators

4. Pipeline Products
4.1 Changes to Antimicrobeals, 2016-2022
4.2 Changes to Mucolytic Agents, 2016-2022
4.3 Changes to Pancretic Enzymes, 2016-2022
4.4 Changes to CFTR Modulators, 2016-2022

5. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/cslw9m/cystic_fibrosis

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cystic-fibrosis-heat-map-and-analysis-2016-2022---research-and-markets-300390730.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2019)... ... 2019 , ... Xpediant Digital, the leader in DAM Integration ... VP of Product Development. Surace has spent his career developing products, building complex ... Technology & Distribution at HMN, where he led software development, data analytics, and ...
(Date:3/20/2019)... FALLS CHURCH, Va. (PRWEB) , ... March 20, ... ... solutions and services for Federal and state public health agencies, today announced the ... With more than 15 years of professional consulting and contracts management experience supporting ...
(Date:3/20/2019)... AUSTIN, Texas (PRWEB) , ... ... ... HealthCarePoint (HCP), today announced release of ground-breaking mechanisms specifically designed ... care, stay in compliance with local and international regulations and continue to ...
Breaking Medicine Technology:
(Date:3/20/2019)... (PRWEB) , ... March 20, 2019 , ... ... Medical systems are being developed with Wi-Fi connectivity to allow portable devices to ... heart and hypertension monitoring, glucose monitoring, and other wearable devices for home healthcare ...
(Date:3/20/2019)... ... March 20, 2019 , ... TSI Healthcare, ... (PM) and Electronic Health Record (EHR) solutions, received multiple top awards in the ... the fifth consecutive year TSI Healthcare has been honored by this selective international ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... pain from disc herniation's, degenerative disc disease, spinal stenosis, sciatica and numbness in ... location! , At Advanced Spine Joint and Wellness provider's work as a ...
(Date:3/20/2019)... CREEK, Calif. (PRWEB) , ... March 20, 2019 ... ... for the healthcare industry, announced today the launch of its mSource® Predictive Plan, ... customers the most complete insights. It gives purchased services teams the control to ...
(Date:3/20/2019)... ... March 20, 2019 , ... AutismOne has announced that Dr. Andrew Wakefield, an ... measles. Dr. Wakefield's presentation at the AutismOne 2019 Conference will address what herd immunity ... eras. The lecture will examine the consequences - real and potential - for vaccines ...
Breaking Medicine News(10 mins):